Aosaikang Pharmaceutical sees profit more than double, revenue up

Beijing Aosaikang Pharmaceutical reported a net profit attributable to shareholders of 159,987,130.87 yuan for the first half of 2025, marking a 111.64% increase year-on-year. Operating revenue also rose by 9.20% to 1,007,412,827.96 yuan. This performance is largely driven by strong sales in chronic disease and oncology products. The company's total assets increased by 8.86% to 4,406,156,170.35 yuan.

The board of directors convened on August 28, 2025, to approve the semi-annual report and several revisions to the company's governance documents, including its articles of association and various management policies. These revisions will be presented for shareholder approval at the Second Extraordinary General Meeting of 2025 on September 19, 2025. The company plans no cash dividends, bonus shares, or capital increases from the provident fund for this period.

The company continues to prioritize R&D, with investments of 201,749,537.03 yuan during the reporting period, contributing to its sustained growth and competitive edge. AskGene Limited, a significant non-wholly owned subsidiary, reported a net loss of -32,819,839.78 yuan but also generated a comprehensive income of -33,928,467.68 yuan.